

PHARMACEUTICAL & THERAPEUTICS (P&T) COMMITTEE
Connecticut Medical Assistance Program

Thursday May 7th, 2020 6:00 pm – 10:00 pm

Department of Social Services

Due to the COVID-19 outbreak, the Meeting will be conducted via teleconference.

AGENDA

Opening Remarks

Department of Social Services

Brief communication regarding COVID-19

New Business

Approval of Updated P&T Bylaws

Carl Sherter, Chair

Nomination/Election of Chairperson

Carl Sherter, Chair

Nomination/Election of Vice Chairperson

Carl Sherter, Chair

Approval of Minutes

Carl Sherter, Chair

November 14th, 2019 Meeting

Therapeutic Class Reviews

Kathy Novak, Magellan

Public Presentations

1. ANTICOAGULANTS

a. Eliquis

Afraim Botros, PharmD, Bristol Myers Squibb

2. ANTIMIGRAINE AGENTS, OTHER

a. Ajovy

Paul J. Isikwe, PharmD, Teva

b. Nurtec ODT

Tammy Martin, BSN, MS, APRN, FNP, Biohaven

c. Aimovig

Gene Muise, RPh., MSc., Amgen

d. Reyvow, Emgality

Elizabeth Lubelczyk, PharmD, Eli Lilly

e. Ubrelvy

Patricia Jacob PharmD, Allergan

3. ANTIVIRALS, ORAL

a. Xofluza

Sharmi Patel, PharmD, Genetech

4. BETA-BLOCKERS

a. Hemangeol

Christine Cazeau, MD, Pierre Fabre

5. GLUCAGON AGENTS

a. Baqsimi

Elizabeth Lubelczyk, PharmD, Eli Lilly

6. GROWTH HORMONE

a. Genotropin

Jean C. McGrath Brodeur, PharmD, Pfizer

7. HEPATITIS C AGENTS

a. Mavyret

Sarah Hnath, PT, DPT, AbbVie

8. HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS

a. Rybelsus

Egils Bogdanovics, MD, Hartford HealthCare

- b. Rybelsus, Ozempic
- c. Rybelsus
- d. Trulicity

9. HYPOGLYCEMICS, INSULIN AND RELATED AGENTS

- a. Tresiba

10. LIPOTROPICS, OTHER

- a. Repatha

11. OPIATE DEPENDENCE TREATMENTS

- a. Sublocade

12. PAH AGENTS, ORAL AND INHALED

- a. Orenitram ER
- b. Opsumit, Uptravi

13. PANCREATIC ENZYMES

- a. Creon

14. UTERINE DISORDER TREATMENTS

- a. Orilissa

David J Domenichini MD, Endocrinology & Internal
 Tammy Kell, Novo Nordisk
 Elizabeth Lubelczyk, PharmD, Eli Lilly

Egils Bogdanovics, MD, Hartford HealthCare

Gene Muise, RPh., MSc., Amgen

William Mullen PA, MPH, Indivior

Melinda Given, PhD., MSL, United Therapeutics
 David Lopez, PhD, Actelion

Sarah Hnath, PT, DPT, AbbVie

Sarah Hnath, PT, DPT, AbbVie

- 15. ACNE AGENTS, TOPICAL
- 16. ANALGESICS, NARCOTICS SHORT
- 17. ANDROGENIC AGENTS
- 18. ANGIOTENSIN MODULATOR COMBINATIONS
- 19. ANGIOTENSIN MODULATORS
- 20. ANTIBIOTICS, GI
- 21. ANTIBIOTICS, INHALED
- 22. ANTIBIOTICS, TOPICAL
- 23. ANTIBIOTICS, VAGINAL
- 24. ANTIEMETIC/ANTIVERTIGO AGENTS
- 25. ANTIFUNGALS, ORAL
- 26. ANTIFUNGALS, TOPICAL
- 27. ANTIMIGRAINE AGENTS, TRIPTANS
- 28. ANTIPARASITICS, TOPICAL
- 29. ANTIVIRALS, TOPICAL
- 30. BLADDER RELAXANT PREPARATIONS
- 31. BONE RESORPTION SUPPRESSION AND RELATED AGENTS
- 32. BPH TREATMENTS
- 33. CALCIUM CHANNEL BLOCKERS
- 34. CEPHALOSPORINS AND RELATED ANTIBIOTICS
- 35. CONTRACEPTIVES, ORAL
- 36. FLUOROQUINOLONES, ORAL

- 37. GI MOTILITY, CHRONIC
- 38. GROWTH FACTORS
- 39. H. PYLORI AGENTS
- 40. HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS
- 41. HYPOGLYCEMICS, MEGLITINIDES
- 42. HYPOGLYCEMICS, METFORMINS
- 43. HYPOGLYCEMICS, SGLT2
- 44. HYPOGLYCEMICS, TZD
- 45. IMMUNOSUPPRESSIVES, ORAL
- 46. LIPOTROPICS, STATINS
- 47. MACROLIDES/KETOLIDES
- 48. MULTIPLE SCLEROSIS AGENTS
- 49. PHOSPHATE BINDERS
- 50. PITUITARY SUPPRESSIVE AGENTS, LHRH
- 51. PLATELET AGGREGATION INHIBITORS
- 52. POTASSIUM BINDERS
- 53. PRENATAL VITAMINS
- 54. PROTON PUMP INHIBITORS
- 55. SKELETAL MUSCLE RELAXANTS
- 56. TETRACYCLINES
- 57. ULCERATIVE COLITIS AGENTS
- 58. VASODILATORS, CORONARY

New Generics to Market

Kathy Novak / Magellan

Other Business

Recommendations for next class reviews
 Fall 2020 Meeting Date Discussion
 Adjourn

Kathy Novak / Magellan